Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Thermostabilized single vial vaccine targeting Sudan and Marburg filoviruses protects 100% of non-human primates against lethal Sudan ebolavirus challenge
https://ir.soligenix.com/2021-12-02-Soligenix-Announces-Successful-Protection-using-a-Bivalent-Thermostabilized-Filovirus-Vaccine
AWESOME!!
This is my watch list for lithium...
Symbol Bid Ask Price Chg ($) Chg (%) Open High Low Volume
LITH
0.51 1.10 0.0001 0.00 0.00% -- -- -- --
LTUM
0.251 0.2894 0.26 -0.0152 -5.52% 0.27 0.27 0.251 335.78K
AMLM
0.272 0.284 0.2834 -0.0176 -5.85% 0.2925 0.309 0.2705 248.32K
EOSE
9.05 9.25 9.06 -0.89 -8.94% 10.22 10.22 9.04 562.79K
LTHM
28.35 28.60 28.35 -1.94 -6.40% 30.87 31.69 28.49 3.09M
LAC
34.60 35.40 34.60 -4.71 -11.98% 37.64 38.31 34.88 9.46M
ENR
36.82 38.26 37.24 0.05 0.13% 37.72 38.29 37.15 624.22K
SQM
60.59 61.69 61.73 -0.53 -0.85% 63.69 64.88 60.65 1.17M
CHWY
66.01 66.49 66.49 -1.77 -2.59% 68.62 69.38 65.32 6.92M
PSX
68.41 69.80 68.67 -0.50 -0.72% 71.40 71.8348 68.63 3.98M
JCI
74.57 75.39 74.97 0.21 0.28% 76.39 77.93 74.93 3.69M
LIT
91.00 91.50 91.35 -1.64 -1.76% 93.88 94.37 91.23 1.39M
FMC
92.15 100.10 100.10 -0.09 -0.09% 102.60 104.34 100.14 788.52K
ALB
260.00 269.84 260.00 -6.49 -2.44% 270.01 276.00 259.80 1.25M
5:52:53 pm ET 12/1/21
Just so you know I haven't done much DD but these are from my quick scan with only a quick review mostly on finviz. I need to look at them more closely and now may be the time to do so.
I still see more market downside though there is this...
There are cracks everywhere...
I posted this on Monday....
"Check out the bounce on the YEN. The markets continue to over perform as the Feds continue to dig our hole deeper and deeper.
Certainly debt based market can perform on "future expectation" though on thin air? It worked for Japan into negative interest rates but it isn't "ever ending".
The clock is ticking. And the inflation is only just beginning. Those that have been getting "free money" will feel the pinch even more, especially if they haven't been able to squirrel some away into savings. Though Biden will likely continue the handouts.
Crazy. No doubt about it.
https://finviz.com/futures_charts.ashx?p=d1&t=6J "
Many of the stocks I'm watching are still breaking support levels. I've been nibbling a few here and there though as I look more and more my charts are going further and further out. I'm thinking this pull back is far from over.
There are cracks everywhere
The "end of year discounts". With a low at $3 it's still a lower low. But worth a nibble imo.
Good luck!
Weekly chart says go for it. Daily says, ehhhhh. I'll take a few here though.
From USPTO...
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11,185,523.PN.&OS=PN/11,185,523&RS=PN/11,185,523
Clearly this is not a small deal. Certainly need to do a bit more dd on this but also glad I stumbled on this little bio.
Edit: Yeah, I think someone found the patent before the company had a chance to release the PR. Just released on Nov 30, 2021 but I didn't see a time.
excerpt...
SUMMARY
In one embodiment, the disclosure includes a method of treating cancer (solid tumor) in a mammal (e.g. human) comprising a) administering to the mammal a bipolar trans carotenoid salt having the formula: YZ-TCRO-ZY where: Y=a cation which can be the same or different, Z=a polar group which can be the same or different and which is associated with the cation, and TCRO=a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen, b) administering to the mammal radiation therapy, wherein said bipolar trans carotenoid salt is administered at time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said radiation.
In a preferred embodiment, the bipolar trans carotenoid is TSC administered at a dose of 0.15-0.35 mg/kg 45-60 minutes prior to administration of said radiation therapy. In some embodiments, the subject mammal is also administered chemotherapy in addition to the radiation therapy, e.g. administering temozolomide 7 times per week for 6 weeks.
A still further embodiment of the disclosure relates to a method of treating cancer (solid tumor) in a mammal (e.g. human) comprising a) administering to the mammal a bipolar trans carotenoid salt having the formula: YZ-TCRO-ZY where: Y=a cation which can be the same or different, Z=a polar group which can be the same or different and which is associated with the cation, and TCRO=a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen, b) administering chemotherapy to the mammal, wherein said bipolar trans carotenoid salt is administered at a time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said chemotherapy.
In a preferred embodiment, TSC administered at a dose of 0.75-2.0 mg/kg 1-2 hour prior to administration of said chemotherapy.
The cancer is selected from the group consisting of squamous cell carcinomas, melanomas, lymphomas, sarcomas, sarcoids, osteosarcomas, skin cancer, breast cancer, head and neck cancer, gynecological cancer, urological and male genital cancer, bladder cancer, prostate cancer, bone cancer, cancers of the endocrine glands (e.g. pancreatic cancer), cancers of the alimentary canal, cancers of the major digestive glands/organs, CNS cancer, and lung cancer. The chemotherapy is selected from the group consisting of alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, and anti-microtubule agents. In some embodiments, the subject mammal is also administered radiation therapy in addition to the chemotherapy.
In an advantageous embodiment, the bipolar trans carotenoid is TSC administered at a dose of 0.75-2.0 mg/kg, 1-2 hrs. prior to administration of said chemotherapy. The chemotherapy is one or more compounds selected from the group consisting of gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.
In one embodiment, the method is administering 1.5 mg/kg TSC 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering gemcitabine as an IV infusion once per week for 3 weeks followed by a week of rest.
In another embodiment, 1.5 mg/kg TSC is administered 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering nab-paclitaxel as an IV infusion followed by gemcitabine as an IV infusion, once per week for 3 weeks followed by a week of rest.
In another embodiment, the subject disclosure relates to a method of treating a cancer of the pancreas in a mammal (e.g. human) comprising: a) administering to the mammal a bipolar trans carotenoid salt having the formula: YZ-TCRO-ZY where: Y=a cation which can be the same or different, Z=a polar group which can be the same or different and which is associated with the cation, and TCRO=a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen, and b) administering to the mammal chemotherapy, wherein the bipolar trans carotenoid salt is administered at a time and at a dose causing increased partial pressure of oxygen in the tumor during administration of the chemotherapy.
In an advantageous embodiment, the bipolar trans carotenoid is TSC administered at a dose of 0.75-2.0 mg/kg, 1-2 hrs. prior to administration of said chemotherapy. The chemotherapy is one or more compounds selected from the group consisting of gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.
In one embodiment, the method is administering 1.5 mg/kg TSC 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering gemcitabine as an IV infusion once per week for 3 weeks followed by a week of rest.
In another embodiment, 1.5 mg/kg TSC is administered 45-60 minutes prior administering the chemotherapy, and administering the chemotherapy is administering nab-paclitaxel as an IV infusion followed by gemcitabine as an IV infusion, once per week for 3 weeks followed by a week of rest.
The disclosure also relates to a method of treating a cancer of the brain (e.g. glioblastoma) in a mammal (e.g. human) comprising: a) administering to the mammal a bipolar trans carotenoid salt having the formula: YZ-TCRO-ZY where: Y=a cation which can be the same or different, Z=a polar group which can be the same or different and which is associated with the cation, and TCRO=a linear trans carotenoid skeleton with conjugated carbon-carbon double bonds and single bonds, and having pendant groups X, wherein the pendant groups X, which can be the same or different, are a linear or branched hydrocarbon group having 10 or less carbon atoms, or a halogen, and b) administering radiation therapy to the mammal wherein the bipolar trans carotenoid salt is administered at time and at a dose causing increased partial pressure of oxygen in the tumor during administration of said radiation.
When the bipolar trans carotenoid is TSC, it is administered at a dose of 0.15-0.35 mg/kg 45-60 minutes prior to said administration, typically external beam radiation therapy. In one embodiment, the radiation therapy is administering 5 times per week for 6 weeks. In another embodiment, the method includes administering chemotherapy to the mammal, e.g. administering temozolomide 7 times per week for 6 weeks.
In all of the above embodiments, advantageously the bipolar trans carotenoid salt is TSC is in the form of a composition with a cyclodextrin.
Excellent point Giovanni. Companies apply for fast track designation, along with breakthrough and orphan. If granted it can add exclusive marketing rights and give them a little more attention with the FDA.
But, none of it matters if the drug crashes and burns. That's why I mentioned just getting the fast track designation, while it's a good thing, it's not really a money maker. The science and company fundamentals are what counts. But, I'm thinking we'll have more confidence in HEPA's CRV431 as they move through their larger phase 2b trial.
Here's some more info on FDA designations
https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies
Always good to see you Giovanni. You always keep things real.
NEWS: "2021 has proven to be a breakthrough year for distance wireless charging, and the team at Energous is extremely proud to be leading the way," said Cesar Johnston, acting CEO of Energous. "As the pace of digital transformation accelerates, artificial intelligence and other edge processing are pushing the power requirements of connected devices to higher levels. With solutions from 1W to 5.5W and now 10W, Energous' world-leading wireless power technology portfolio allows us to provide a complete platform solution for wireless power networks where traditional wired or battery power is not an option. This is a significant accomplishment, as it opens potential new opportunities for the wireless charging of billions of IoT devices across emerging consumer, retail and industrial markets."
https://ih.advfn.com/p.php?pid=nmona&article=86695482
Now that's somethin
Robert Foster, PharmD, PhD, Hepion’s CEO, added, “This Fast Track designation provides for early and frequent communication with the FDA that will continue throughout the drug development and review process, which may lead to a more expedited drug approval and patient access to CRV431. Additionally, as part of the FDA Fast Track designation for CRV431 in NASH, Hepion will make its expanded access policy publicly available in the coming weeks.”
Just getting started.
I'm playing more off the technicals with a target of 1.80 short term.
HEPA daily chart showing an early sign of reversal. Of course the bottom needs to prove itself which if it holds 1.15 it just may do.
I like the science but I'm more on the technicals. If it pans out, what II keep as a core position will make out nicely.
I've seen much larger floats make CRAZY moves. Fast track is nice but it's not a money maker. But it's nice to have.
Anyway, this has been on my list for some time and only a quick swing once, so far. But like the looks much better now.
https://finviz.com/quote.ashx?t=hepa
Nothing against shorts, a team I trade with is big into shorting. Should be a link on my profile. (fixed it).
Volume kicked in late in the day, nice push!
No position. Was busy with leaves, just a few billion more to bag up.
Seems the market wants to deflate not that many weren't ready for it. Just a matter of when. Picking up a bit more downside momentum. Buckle up. 2.12 bottom broke. New covid strain to blame or maybe that's just a Fed excuse to put their trillion in cheaper stocks?
Watching closer. 3.28
Still a gap to fill around 2.25, one thing I hate is gaps. They almost always fill. But, will they be able to hold this one up?
https://finviz.com/quote.ashx?t=crvs
1.15 triple bottom. Trip and rips can be very volatile. Gets near the $ I'll be adding big time. There's a few others I'm watching but no one knows what'll happen tomorrow in this market. Thinking if the markets were as green as they are red today this would have easily crushed shorty.
Watching ContraFect Shares; Zacks Small-Cap Research Sets $23 Valuation
10:07 am ET November 30, 2021 (Benzinga) Print
Latest Ratings for CFRX DateFirmActionFromTo
Sep 2021SVB LeerinkInitiates Coverage OnOutperform Mar 2021WBB SecuritiesInitiates Coverage OnSpeculative Buy Jun 2020Cantor FitzgeraldInitiates Coverage OnOverweight
View More Analyst Ratings for CFRX
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The company had nothing to do with the $23 valuation.
If I had that answer this would probably be the only bio stock in my portfolio.
Thinking they'll see at least $7 - $10 in 2022. 2nd half.
Looks like there are some trailing stops set, MM's munching them up.
$23 valuation. Don't know about that but sure would love to see it!!
November 30, 2021
10:07 am ET
*ContraFect Shares Halted On Circuit Breaker To Upside; Up 14%
Benzinga
10:07 am ET
Watching ContraFect Shares; Zacks Small-Cap Research Sets $23 Valuation
Benzinga
Far out!
4.38 -4.45 resistance, may cut thru like butter!
Pipeline strengthening! Very interesting indeed. See if the deep pockets take advantage.
https://finance.yahoo.com/news/soligenix-proof-concept-uncovers-potential-133000442.html
Filled my 1.27's. Go $HEPA!!
They want you to vote "yes" for their agenda.
https://finance.yahoo.com/news/iss-joins-glass-lewis-recommending-130000025.html
That reverse split is still on the list. though I forget the ratio.
The only way I don't see it happening is if they fail to meet quorum.
https://www.sec.gov/Archives/edgar/data/1420720/000155837021016064/tmb-20211116xdefa14a.htm
Yesterday was easy money. Still will keep an eye on this after the split.
Target 1.60's - 1'80's (doesn't have to be today but the chart looks close to reversal). Like the looks of this one too to keep a core.
How bout a .15 to .30 pinch? lol, IF that happened it might as well keep going!!
SYN daily, putting this on pinch radar. .345.
Check out the bounce on the YEN. The markets continue to over perform as the Feds continue to dig our hole deeper and deeper.
Certainly debt based market can perform on "future expectation" though on thin air? It worked for Japan into negative interest rates but it isn't "ever ending".
The clock is ticking. And the inflation is only just beginning. Those that have been getting "free money" will feel the pinch even more, especially if they haven't been able to squirrel some away into savings. Though Biden will likely continue the handouts.
Crazy. No doubt about it.
https://finviz.com/futures_charts.ashx?p=d1&t=6J
resistance is now support. Needs to hold the .90. Trailing stop.
quick flip for me anyway. I'm out .945. watching for the retest.
.8999 resistance. Thinking last leg before this dumps.
Shorts are coming in now to close imo. Watch the LII's, doubt it even breaks .94.
Hell of a nice push to help those that wanted to get out.
Watch the daily here. $WATT $1.55.
watching this consolidation closely. Building my position 3.15 to 3.30.
Bring Santa on the set by Friday!!
Volume kicked in big time!!
Wow. You had me at hello. Typical Fed BS on a Friday after a holiday when YOU THINK no one's watching.
Thankfully I was looking forward to seeing just that and have the cash to take advantage, still, seeing the red numbers, and NOT small numbers, is tough. But, if all works out, it'll be major green by next Friday.
Cheers all!!
Someone asked me what I thought the correction would be.
20% Not just 10k off the djia.
Trade wisely.
Very interesting. I didn't even know that was a thing. I know many are waiting for the major correction sooner or later.
For now I'm ready for the Santa Clause rally!!
Cheers! Happy turkey day!
INPX News: Inpixon Recognized as an IDC Innovator for Location & Geospatial Intelligence
https://investorshub.advfn.com/Inpixon-INPX-31856#:~:text=INPX%20News%3A%20Inpixon%20Recognized%20as%20an%20IDC%20Innovator%20for%20Location%20%26%20Geospatial%20Intelligence
$SYN kicking up a little momentum. Need a volume breakout!
SYN daily
Chart looks ready to go imo. Pretty impressive news imo.
Watching closer. New starter 1.19
Looks like she may be trying to prove a reversal.
INPX daily
RCAT 2.19 todays low 2.155. 2.12 double bottom on the 3 to 6 month. Not quite ready to bounce yet but I'm still looking to accumulate more here. Price alert set 2.12. I told myself not to go too big on something that's dipping, though it doesn't always work out but adding when the pinch is setting up or at least after the lower lows stop printing I usually make out pretty good. So That's what I'm waiting for.
RCAT daily
I'm thinking they snag a partner or merge 1H 2022.
CFRX 3.36. SNGX .8714 and DFFN .39 may have a chance
CFRX daily
SNGX daily
DFFN daily